Posted 19 January 2020 PM
Australia seems to have its eye on the single-dose Johnson & Johnson COVID-19 vaccine, with confirmation from the company's pharmaceutical division Janssen that it is working in "close collaboration" with the TGA to gain provisional registration.
J&J is in the final stages of data analysis for its phase 3 trial with the release of its efficacy numbers expected "very soon" in the words of CEO Alex Gorsky.